We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » inVentiv Health to acquire PharmaNet

inVentiv Health to acquire PharmaNet

May 17, 2011
CenterWatch Staff

InVentiv Health, a service provider to the healthcare industry, has signed a definitive agreement to purchase CRO PharmaNet Development Group. Financial terms of the transaction were not disclosed.

With the addition of PharmaNet, inVentiv said it will extend its global presence to nearly 40 countries and enhance both its early- and late-stage clinical development capabilities. In conjunction with its previously announced agreement to acquire CRO i3, inVentiv Health said it will be positioned for accelerated growth in the $21 billion global pharmaceutical outsourcing industry.  

Following the acquisitions, inVentiv will have 13,000 employees in three divisions: Clinical, Commercial and Consulting. More than 6,000 employees will be dedicated to clinical research worldwide, including emerging markets in Asia, Latin America and Central/Eastern Europe.

InVentiv said the acquisitions will provide the scale and scope to participate in strategic alliances of any size and will give inVentiv greater opportunities for growth as pharmaceutical companies continue to increase outsourcing to enhance flexibility and lower fixed costs.

"One of our key strategic objectives is to be recognized as the leader in every segment where we serve our clients," said Paul Meister, CEO of inVentiv Health.  "The acquisition of PharmaNet positions us among the top global CROs, increasing our capabilities, adding new expertise in every phase of clinical development, and strengthening our impressive client base and strong management team."

Jeffrey P. McMullen, President and CEO of PharmaNet, said, "Our team is fully committed to continuing to grow our business and executing on the future opportunities that this combined offering provides to both our customers and employees."

McMullen, who will lead inVentiv's CRO businesses, said he chose to work with inVentiv because the organizations share the same client-centric approach and strong therapeutic expertise in oncology, rheumatology and neuroscience, as well as in clinical technologies. "In the day-to-day operations, little will change.  We will continue to provide the same level of exceptional service that our clients have come to expect of us."  

PharmaNet offers drug development capabilities and expertise in phase I through IV clinical trials, bioanalytical services, pharmaceutical and regulatory consulting and staffing. About half of PharmaNet's revenue is generated outside the United States.

"In the evolving global market, scale is a key competitive advantage to developing strategic relationships with our clients. This acquisition allows us to achieve critical scale while providing enhanced services to our clients any time they need them, anywhere in the world," Meister said.

BofA Merrill Lynch, Citi and Jefferies Finance provided financing commitments to inVentiv Health to support the transaction. Jefferies & Company and UBS Securities acted as financial advisor to PharmaNet. The transaction is subject to customary closing conditions and is anticipated to close on or about June 30, 2011.  

inVentiv Health is privately owned by inVentiv Group Holdings, an organization sponsored by affiliates of Thomas H. Lee Partners, Liberty Lane Partners and members of the inVentiv management team.

PharmaNet was acquired in 2009 by JLL Partners, a New York-based private equity investment firm. Ramsey A. Frank, a JLL partner, said, "We are very proud of the significant accomplishments PharmaNet has achieved. We have worked in close partnership with the company's management team to drive operational efficiencies and outstanding new business momentum."

 

Global News CROs/Service Providers

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing